This study was conducted by exploring the expression and prognostic value of FXYD2 and its relationship with immune microenvironment in ccRCC to improve the practice of immunotherapy for better prognosis of ccRCC patients. Here, FXYD2 is linked to nonpapillary renal cell carcinoma.